MDMA should be licensed for veterans with PTSD
The Spectator, September 20, 2025
The documentary Dead Dog on the Left chronicles the journey through the no-man’s land of complex PTSD, which in turn triggered alcoholism and suicidal thoughts, to an eventual recovery, aided by MDMA-led psychotherapy.
Depression remission endures 5 years after psilocybin trial
Osu.Edu, September 10, 2025
Two-thirds of clinical trial participants treated with psilocybin-assisted therapy for major depressive disorder were in complete remission from their depression five years later, a new study has found.
Tryptamine secures landmark EEG biomarker deal to advance precision psychiatry
The Australian, August 22, 2025
Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin Carhart-Harris and Professor Pedro Mediano to develop a first-of-its-kind electroencephalogram (EEG) based brain entropy biomarker.
Australian-first psychedelic-assisted therapy trial for terminally ill patients shows improved quality of life
ABC News, August 20, 2025
A small psychedelic-assisted therapy trial shows rapid and sustained reductions in depression and anxiety, while improving overall quality of life.
Oregon sees 1,500 users access psilocybin services in four months
Koin, July 29, 2025
More than 1,500 people accessed psilocybin services between January and April, according to data from the Oregon Health Authority.
Psychedelic Drug May Slow Aging
Newsweek, July 10, 2025
Could psilocybin hold the key to slowing down aging? New research from Georgia’s Emory University suggests they just might.
New Zealand approves psilocybin to treat depression
NZ Ministry of Health, June 19, 2025
Medsafe has given a New Zealand psychiatrist approval to prescribe medicinal psilocybin for treating treatment-resistant depression. This is the first time psilocybin will be prescribed outside of a research setting in New Zealand, and will give people with this severe condition more options.
New Zealand Gives Nod To ‘Magic Mushrooms’ For Medicinal Purpose
MSN, June 18, 2025
New Zealand on Wednesday approved the medicinal use of psilocybin. Deputy Prime Minister David Seymour said rules had been relaxed so psilocybin could be used to treat certain types of depression.
MDMA to treat PTSD? Medibank says Y-E-S
The Australian, June 18, 2025
Emyria (ASX: EMD) has secured the support of Medibank Private (ASX: MPL) to fund the company’s post-traumatic stress disorder (PTSD) care program it has developed through the Perth Clinic. The agreement is the first for a major private health insurer funding a psychotherapy-led PTSD program in Australia, allowing Emyria to offer patients its Empax PTSD treatment without any out-of-pocket expenses.
Czech Republic opens door to psychedelic therapies for mental health conditions
Parea, June 5, 2025
In a recent vote, the Czech Parliament passed legislation that paves the way for qualified psychiatrists to administer psilocybin in accredited medical facilities as part of assisted psychotherapy.
Psilocybin and IBS treatment: First psychedelic study in gastroenterology
Open Access Government, June 5, 2025
In a groundbreaking first, psilocybin is entering gastroenterology.
Emyria reports promising PTSD recovery data 6 months after treatment
Next Investors, May 28, 2025
63% of patients no longer met the PTSD criteria, with symptoms dropping 55.5% on average.
Psychedelic ‘wonder drug’ of the ‘60s can improve Parkinson’s symptoms for weeks
NY Post, May 1, 2025
Psilocybin — the psychedelic compound that gave “magic mushrooms” their trippy reputation in the 1960s — is now showing serious promise for improving mood and motor function in people with Parkinson’s disease, according to a groundbreaking recent study.
How Do Psychedelics Battle Stress? Scientists Find Their Influence Extends Beyond the Brain
Singularity Hub, April 25, 2025
The medicines disrupted communication between the brain and immune system to lower stress in mice.
Psychedelic Mushroom Market To Surpass $3.3 Billion By 2031, Report Predicts
Forbes, March 21, 2025
The use of psychedelic mushrooms is on the rise, and a new report confirms the expansion of the market with growing interest in psilocybin and its potential applications in therapy.
The Colorado psychedelic mushroom experiment has arrived
CBS News, March 19, 2025
Colorado regulators are issuing licenses for providing psychedelic mushrooms and are planning to authorise the state’s first “healing centers,” where the mushrooms can be ingested under supervision, in late spring or early summer.
Psychedelic therapy may soon be funded for veterans with PTSD, depression
ABC, March 4, 2025
The DVA plans to finalise its assessment guidelines for psychedelic-assisted therapies later this year.
Treatments like MDMA and psilocybin to be funded for veterans
ABC News, March 4, 2025
Australian veterans suffering from PTSD and depression will soon have access to a new form of treatment.
Emyria says MDMA works for PTSD, months after treatment
Stockhead, February 4, 2025
Emyria lead psychiatrist Dr Jon Laugharne says these “sustained benefits” suggest that MDMA-assisted therapy “has the potential to create lasting impacts for individuals who have struggled with severe and treatment-resistant PTSD.”
Innovative trial will use psilocybin to target relapse in opioid addiction
Imperial College, October 18, 2024
Imperial researchers will explore the potential for psilocybin therapy in drug recovery as part of a landmark trial.
A ‘first in the UK’ clinical trial exploring the use of psychedelics in addiction.